Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03505320
Title A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (ILUSTRO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma



Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab

Pembrolizumab + Zolbetuximab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA

No variant requirements are available.